Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anabolic_steroid
|
| gptkbp:activeIngredient |
gptkb:methandrostenolone
|
| gptkbp:alsoKnownAs |
gptkb:Dianabol
|
| gptkbp:bannedIn |
gptkb:World_Anti-Doping_Agency
|
| gptkbp:broadcastOn |
gptkb:Schedule_III_(US)
|
| gptkbp:legalStatus |
controlled substance in many countries
|
| gptkbp:manufacturer |
British Dispensary
|
| gptkbp:marketedIn |
gptkb:Thailand
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
water retention
high blood pressure liver toxicity gynecomastia |
| gptkbp:usedFor |
performance enhancement
muscle growth |
| gptkbp:bfsParent |
gptkb:methandrostenolone
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Danabol DS
|